Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

Published:2018-11-07 Issue:2 Volume:37 Page:331-337
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Barata Pedro C.,Cooney Matthew,Mendiratta Prateek,Gupta Ruby,Dreicer Robert,Garcia Jorge A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-018-0687-5.pdf

Reference49 articles.

1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30

2. Sartor O, de Bono JS (2018) Metastatic prostate cancer. N Engl J Med 378(7):645–657

3. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

4. Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate Cancer. N Engl J Med 351(15):1513–1520

5. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy;Prostate Cancer and Prostatic Diseases;2024-01-31

2. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis;Molecular Oncology;2024-01-15

3. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease;Signal Transduction and Targeted Therapy;2023-10-02

4. Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence;Expert Opinion on Therapeutic Targets;2023-08-03

5. Angiogenesis and prostate cancer: MicroRNAs comes into view;Pathology - Research and Practice;2023-08